Skip to main content
OTCMKTS:SKBI

Skystar Bio-Pharmaceutical Competitors

$0.0000
0.00 (0.00 %)
(As of 03/25/2019)
Add
Compare
Today's Range
$0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
$0.01
Volume25 shs
Average Volume1,983 shs
Market Capitalization$87.00
P/E RatioN/A
Dividend YieldN/A
Beta-175.12

Competitors

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) Vs. ACUS, AFFY, ARYX, AHROQ, CBPI, and CDSG

Should you be buying SKBI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Skystar Bio-Pharmaceutical, including Acusphere (ACUS), Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), and China Dongsheng International (CDSG).

Acusphere (OTCMKTS:ACUS) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Acusphere and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/A

Risk & Volatility

Acusphere has a beta of -0.25, suggesting that its share price is 125% less volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, suggesting that its share price is 17,612% less volatile than the S&P 500.

Valuation and Earnings

This table compares Acusphere and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current ratings for Acusphere and Skystar Bio-Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
Skystar Bio-Pharmaceutical0000N/A

Summary

Acusphere beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Affymax (OTCMKTS:AFFY) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Profitability

This table compares Affymax and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/A

Risk & Volatility

Affymax has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, suggesting that its share price is 17,612% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Affymax and Skystar Bio-Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Skystar Bio-Pharmaceutical0000N/A

Valuation and Earnings

This table compares Affymax and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/AN/AN/A

Summary

Affymax beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Risk & Volatility

ARYx Therapeutics has a beta of -0.53, indicating that its share price is 153% less volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, indicating that its share price is 17,612% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for ARYx Therapeutics and Skystar Bio-Pharmaceutical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Skystar Bio-Pharmaceutical0000N/A

Profitability

This table compares ARYx Therapeutics and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/A

Valuation & Earnings

This table compares ARYx Therapeutics and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/AN/AN/A

Summary

ARYx Therapeutics beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) and AtheroNova (OTCMKTS:AHROQ) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Valuation and Earnings

This table compares Skystar Bio-Pharmaceutical and AtheroNova's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skystar Bio-PharmaceuticalN/AN/AN/AN/AN/A
AtheroNovaN/AN/AN/AN/AN/A

Profitability

This table compares Skystar Bio-Pharmaceutical and AtheroNova's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skystar Bio-PharmaceuticalN/AN/AN/A
AtheroNovaN/AN/AN/A

Volatility and Risk

Skystar Bio-Pharmaceutical has a beta of -175.12, indicating that its stock price is 17,612% less volatile than the S&P 500. Comparatively, AtheroNova has a beta of -8.71, indicating that its stock price is 971% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Skystar Bio-Pharmaceutical and AtheroNova, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skystar Bio-Pharmaceutical0000N/A
AtheroNova0000N/A

Summary

AtheroNova beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

China Botanic Pharmaceutical (OTCMKTS:CBPI) and Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares China Botanic Pharmaceutical and Skystar Bio-Pharmaceutical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Botanic PharmaceuticalN/AN/AN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/AN/AN/A

Profitability

This table compares China Botanic Pharmaceutical and Skystar Bio-Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Botanic PharmaceuticalN/AN/AN/A
Skystar Bio-PharmaceuticalN/AN/AN/A

Volatility & Risk

China Botanic Pharmaceutical has a beta of 17.09, meaning that its stock price is 1,609% more volatile than the S&P 500. Comparatively, Skystar Bio-Pharmaceutical has a beta of -175.12, meaning that its stock price is 17,612% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for China Botanic Pharmaceutical and Skystar Bio-Pharmaceutical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Botanic Pharmaceutical0000N/A
Skystar Bio-Pharmaceutical0000N/A

Summary

China Botanic Pharmaceutical beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.

Skystar Bio-Pharmaceutical (OTCMKTS:SKBI) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Profitability

This table compares Skystar Bio-Pharmaceutical and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Skystar Bio-PharmaceuticalN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Skystar Bio-Pharmaceutical and China Dongsheng International, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Skystar Bio-Pharmaceutical0000N/A
China Dongsheng International0000N/A

Volatility & Risk

Skystar Bio-Pharmaceutical has a beta of -175.12, meaning that its stock price is 17,612% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, meaning that its stock price is 1,238% more volatile than the S&P 500.

Valuation & Earnings

This table compares Skystar Bio-Pharmaceutical and China Dongsheng International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skystar Bio-PharmaceuticalN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Summary

China Dongsheng International beats Skystar Bio-Pharmaceutical on 1 of the 1 factors compared between the two stocks.


Skystar Bio-Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Acusphere logo
ACUS
Acusphere
0.0$0.05flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.06flat$0.00N/A0.00High Trading Volume
Gap Up
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00High Trading Volume
Gap Down
CBPI
China Botanic Pharmaceutical
0.0$0.08flat$0.00N/A0.00High Trading Volume
Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.06flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.25flat$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$31.78flat$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.80flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05flat$0.00N/A0.00Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Up
PARD
Poniard Pharmaceuticals
0.5$0.09flat$0.00N/A0.00Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05flat$0.00$26.09 million0.00Gap Down
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03flat$0.00N/A0.00Gap Up
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01flat$0.00N/A0.00
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.